International hematology expert Dr. John Pagel recruited to expand Swedish’s treatment for, and research on, blood cancers
SEATTLE — September 8, 2014 — The Swedish Cancer Institute is launching a Hematologic Malignancies program for the expanded treatment and research of blood-based cancers such as leukemia, multiple myeloma and lymphoma. Newly recruited international hematology expert John Pagel, M.D., Ph.D., will serve as chief of the new program, which launches this month.
“Dr. Pagel brings with him a world-class reputation for research and excellence in patient care,” said Swedish Cancer Institute Executive Director Thomas Brown, M.D. “This new program will add to our existing strengths in caring for patients with hematologic malignancies and further develop our autologous hematopoietic stem cell program. These efforts allow the Swedish Cancer Institute to continue providing the most versatile and comprehensive cancer care in the Pacific Northwest.”
Dr. Pagel’s practice will include caring for patients with acute and chronic leukemias, multiple myeloma, Hodgkin and non-Hodgkin lymphomas, and myelodysplastic syndromes, as well as other myeloproliferative disorders. In addition to providing established treatments such as autologous stem cell transplants, the program will develop novel therapies for the treatment of blood-based diseases through research collaborations and studies initiated by Swedish Cancer Institute physicians.